Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • 5 hours ago

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

LISRAYA's recent approval gives ROIV a nice commercial foundation, while additional indications could turn brepocitinib into a broader immunology franchise. ROIV's pulmonary asset with mosliciguat is also promising. This candidate may be helpful for vascular resistance and walking distance improvements. I believe mosliciguat could over time become a valuable pulmonary franchise, but we still need to see how its subsequent Phase 3 plays out.

Seeking Alpha • Sep 13, 2026

Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha • Sep 10, 2026

Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha • Sep 9, 2026

Roivant's experimental lung disease drug meets goals in mid-stage study

Roivant said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with ​high blood pressure associated with a type of lung ‌disease, sending shares up about 20% in premarket trading.

Reuters • Sep 8, 2026

Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript

Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript

Seeking Alpha • Sep 8, 2026

Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate

Pulmovant, a clinical-stage biotech and Roivant (NASDAQ:ROIV) company, on Tuesday shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Benzinga • Sep 8, 2026

Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha • Sep 8, 2026

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

BASEL, Switzerland and LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. The results will be presented today at the European Respiratory Society (ERS) International Congress 2026.

GlobeNewsWire • Sep 8, 2026

Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. The results will be presented today at the European Respiratory Society (ERS) International Congress 2026.

GlobeNewsWire • Sep 8, 2026